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While  a  number  of endogenous  risk  factors  including  age  and  genetics  are established  for  Alzheimer’s
disease  (AD),  identiﬁcation  of acquired,  potentially  preventable  or treatable  causes,  remains  limited.  In
this paper,  we  review  three  epidemiologic  case  studies  and  present  extensive  biologic,  immunologic
and  anatomic  evidence  to  support  a  novel  hypothesis  that  Bordetella  pertussis  (BP), the  bacterium  better
known to cause  whooping  cough,  is  an important  potential  cause  of  AD.  Cross-cultural  documentation  of
nasopharyngeal  subclinical  BP  colonization  reﬂecting  BP-speciﬁc  mucosal  immunodeﬁciency,  proximate
anatomy  of intranasal  mucosal  surfaces  to central  nervous  system  (CNS)  olfactory  pathways,  and  mech-
anisms by  which  BP  and  BP  toxin  account  for  all hallmark  pathology  of  AD  are  reviewed,  substantiating
biologic  plausibility.  Notably,  respiratory  BP infection  and BP  toxin  secreted  from  subclinical  BP  coloniza-
tion  can  account  for the  initiation  and  accumulation  of  amyloid   plaques  and  tau  tangles.  Additional
mechanisms  consistent  with  the  immunobiologic  effects  of  subclinical  BP  colonization  include  microglial
activation  and  inﬂammation,  atrophy  and  neurodegeneration,  excitotoxicity,  distinctive  anatomic  dis-
tribution  and  sequential  spread  of  disease,  impaired  glucose  utilization,  and  other  characteristic  CNS
pathology  of  AD.  We  conclude  by  assessing  the evidence  for  causation  against  the  Bradford  Hill  criteria,
inves
hor(sand  advocate  for  further  
© 2016  The  Aut
. IntroductionFirst described in 1907 (Alzheimer, 1907), Alzheimer’s dis-
ase (AD) is a neurodegenerative disorder characterized by slowly
rogressive cognitive and behavioral impairment in those with
Abbreviations: AD, Alzheimer’s disease; BP, Bordetella pertussis; CNS, central
ervous system; A, amyloid ; NFT, neuroﬁbrillary tangle; APOE, apolipopro-
ein E; HSV-1, herpes simplex virus-1; APP, A precursor protein; BACE-1, -site
myloid precursor protein-cleaving enzyme; US, United States; wPV, whole cell
ertussis vaccine; aPV, acellular pertussis vaccine; SCBPC, subclinical Bordetella per-
ussis colonization; DPT, diphtheria pertussis and tetanus vaccine; PCR, polymerase
hain reaction; CDC, Centers for Disease Control and Prevention; CVO, circumven-
ricular organ; BBB, blood-brain barrier; kDa, kilodalton; CSF, cerebrospinal ﬂuid;
AMP, cyclic adenosine monophosphate; PKA, protein kinase A; Th1, T helper 1;
h17, T helper 17; mRNA, messenger ribonucleic acid; IL-1, interleukin 1; TNF-
,  tumor necrosis factor-; IL-6, interleukin 6; GABAB, gama-aminobutyric acid B;
DNF, brain-derived neurotrophic factor; CGRP, calcitonin gene-related peptide;
APP, soluble amyloid precursor protein ; GSK3, glycogen synthase kinase 3;
TP, adenosine triphosphate; NAD+, nicotinamide adenine dinucleotide; NADPH,
icotinamide adenine dinucleotide phosphate; GLUT4, glucose transporter 4; GRK2,
-protein-coupled receptor kinase 2; GA, Golgi apparatus; ER, endoplasmic reticu-
um; PS, presenilin; MS,  multiple sclerosis.
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intracellular cerebral neuroﬁbrillary tangles (NFTs) composed of
abnormal tau protein, and extracellular plaques composed of
amyloid- (A)  peptides (Hyman et al., 2012; McKhann et al.,
2011). Concordance rates for AD in monozygotic twins vary from
21 to 83% (Gatz et al., 2006; Breitner et al., 1995; Räihä et al., 1996),
the wide range in part related to differences in study design and
acquired risk factors (Gatz et al., 2006). Notably, when a genome-
wide analysis of genetic loci associated with Alzheimer’s disease
was unable to expand the power of AD prediction models beyond
age, sex and apolipoprotein E (APOE) status alone (Seshadri et al.,
2010), a call was  raised to shift the search for causes of AD “back
to the environment” (Pedersen, 2010). In this respect, a role for
infection in the pathogenesis of AD has been previously suggested
(Honjo et al., 2009; MacDonald, 1988), and in a recent editorial,
33 AD researchers and clinicians “propose that further research on
the role of infectious agents in AD causation.  . .is justiﬁed”(Itzhaki
et al., 2016).
Several neurotropic infections have been associated with
AD, including Chlamydia pneumoniae, Borrelia burgdorferi, and
Toxoplasma gondii,  though not all investigators conﬁrm these asso-
ciations (Hammond et al., 2010; Nicolson, 2008; Kusbeci et al.,
2011). It is plausible that chronic infections, particularly neu-
rotropic infections, contribute to AD. For example, CNS Herpes
Simplex Virus-1 (HSV-1) increases the risk of AD in carriers of the
ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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POE4 allele (Itzhaki and Wozniak, 2008), and mouse brain cells
nfected with HSV-1 show increased levels of the A precursor
rotein (APP) cleaving enzyme BACE-1 (-site amyloid precur-
or protein-cleaving enzyme) and increased A deposits (Wozniak
t al., 2007). Still other investigations have demonstrated that A
as broad-spectrum antimicrobial properties, raising the possibil-
ty that this hallmark of AD is an evolutionary response to bacterial
xposure (Soscia et al., 2010). Corynebacterium diphtheriae, which
nfects the human nasopharynx, has also been proposed to cause AD
ia the passage of diphtheria toxin from olfactory epithelium into
he CNS (Merril, 2012), building on previous work suggesting that
lfactory pathways may  be conduits for microbes and toxins in the
tiology of AD (Mann et al., 1988; Ferreyra-Moyano and Barragan,
989).
Identiﬁed in 1906 (Bordet and Gengou, 1906), Bordetella per-
ussis (BP) is a Gram-negative bacterium that secretes biologically
ctive toxins and causes whooping cough (acute clinical BP). Both
ubclinical and symptomatic BP infections persist in highly vac-
inated populations (Ward et al., 2005; Zhang et al., 2014; de
elker et al., 2006; Hallander et al., 2011; van Boven et al., 2000),
ith escalation of reported whooping cough cases in the past two
ecades in the United States (US) (http://www.cdc.gov/pertussis/
urv-reporting/cases-by-year.html) and many other industrialized
ations (Chiappini et al., 2013). In 2012, it was  noted that “the
revalence of B. pertussis infection is high in [US] adults and increas-
ng at a signiﬁcant rate, especially in individuals more than 65 years
f age” (Weston et al., 2012). In an American study of individuals
ver age 65, BP serology elevations consistent with infection were
etected in 10% of subjects over a three year period, and one-half
o one-third were asymptomatic (Hodder et al., 2000). Multiple lin-
ar regression analysis suggests that between 2006 and 2010 there
ere 465,000 cases of pertussis infection in US adults age 65 and
lder, though only 6369 cases were actually reported (Masseria and
rishnarajah, 2015). In short, Bordetella pertussis insidiously infects
arge numbers of adults, including the elderly, and pertussis rates
ave been rising in recent decades.
Multiple factors are held to play a role in rising US BP rates,
ncluding a reduction in vaccine efﬁcacy when the US switched
rom whole cell pertussis vaccines (wPV) to acellular pertussis vac-
ines (aPV) in the late-1990s due to wPV safety concerns (Winter
t al., 2014). Acellular pertussis vaccines generally contain three or
our puriﬁed, inactivated components of BP, compared to the broad
ntigenic BP proﬁle of wPV prepared from heat or chemically inac-
ivated whole bacteria, and it is generally agreed that the transition
rom wPV to aPV led to less durable immunity (Winter et al., 2014).
n addition, aPV is unable to protect against BP nasopharyngeal col-
nization as demonstrated by Warfel et al. in a non-human primate
odel, and colonized baboons are able to transmit BP infections to
aive baboons in close proximity (Warfel et al., 2014). As such, the
uthors concluded: “that aP [vaccines].  . .fails to prevent coloniza-
ion or transmission provides a plausible explanation for the [US]
esurgence of pertussis.” Complimenting these data, recent phylo-
ynamic analysis and mathematical modeling studies by Althouse
nd Scarpino indicate that while “waning immunity plays a role
n the epidemiology of pertussis’, “asymptomatic transmission is
he most parsimonious explanation for many of the observations
urrounding the resurgence of B. pertussis in the US” (Althouse and
carpino, 2015).
Subclinical BP colonization (SCBPC) infections are here deﬁned
s asymptomatic or mild infections (e.g. transient cough or rhinor-
hea) that elicit minimal or no BP-directed host immunity, thereby
llowing unopposed BP toxin activity in a host. To illustrate the rela-
ionship between BP infection and AD, we ﬁrst apply our hypothesis
o three environmental observations. Evidence of anatomic andlogy 222 (2017) 228–240 229
biological plausibility follow in the third section, and immunobio-
logic mechanisms are discussed in the fourth section of this review.
2. Epidemiologic case studies
2.1. Case 1: the concurrent age-adjusted rise of AD and BP in the
US
Increasing death from AD (Xu et al., 2010) and age-adjusted
risk for AD (Akushevich et al., 2013) in the US since the early
1990s coincide with the commensurate upsurge in BP (Clark, 2014),
the only vaccine-preventable disease in the US increasing in inci-
dence in recent decades (Brooks and Clover, 2006). While limited
to clinically identiﬁed AD cases, and though part of the overall
rise in AD burden in recent decades is due to increased longevity
and a diagnostic shift from diseases with improved survival, we
propose, given the totality of evidence presented below, that the
age-adjusted rise in AD is a true independent increase, and may  be
substantially due to escalating BP infection rates.
Others have proposed that systemic inﬂammatory disease may
drive neurodegeneration in AD (Perry et al., 2007). We  suggest
that systemic inﬂammatory diseases may  contribute to the pro-
gression of AD without being sufﬁcient cause for AD alone. In fact,
many common diseases with an inﬂammatory component, includ-
ing stroke, myocardial infarction, colon cancer, breast cancer, and
rheumatoid arthritis (Akushevich et al., 2013), have decreased in
age-adjusted incidence and mortality as AD incidence has risen.
Additional potential sources of systemic inﬂammation, such as
smoking (CDC, 2011) and periodontal disease (Hugoson et al.,
2008), have also dropped over the same period. In summary,
we submit that generalized inﬂammation alone is insufﬁcient to
explain the increase in AD in recent decades, distinguishing BP as
a speciﬁc potential cause that has risen with AD during the same
period.
2.2. Case 2: vaccination and reduced AD risk
Diphtheria and tetanus vaccines typically, though not exclu-
sively, are co-administered with BP antigens. In a cohort of 3682
non-demented Canadians 65 years of age and older, self-reported
vaccination for diphtheria or tetanus, “considered together, as they
are usually given together in vaccination programs,” correlated
with a statistically signiﬁcant 60% (95% CI 35–75%) lower risk for
the development of AD over ﬁve years during the 1990s (Verreault
et al., 2001). No signiﬁcant association was found between vac-
cination for inﬂuenza and AD, making it unlikely that a boosted
nonspeciﬁc immune or vaccine response alone is AD-protective.
The model adjusted for age, sex, education, alcohol consumption,
family history of dementia, measures of activities of daily living,
antecedents of chronic diseases, and perceived health status. The
cohort percentage that received BP vaccination bundled with diph-
theria or tetanus vaccination was not reported, however it is likely
that a high proportion had simultaneously received pertussis vacci-
nation because: (1) combination diphtheria, pertussis and tetanus
vaccines (DPT), pioneered in Canada, were readily adopted after
introduction in 1943 (Varughese, 1985), (2) DPT administration has
been routine for school vaccination programs in Canada since 1948
(Verreault et al., 2001), and (3) currently, 9 of 11 available prepara-
tions of tetanus toxoid-containing vaccines in Canada are combined
with BP antigens (Canadian Immunization Guide, 2016).
A second independent Canadian study of 694 non-demented
individuals age 65 and over observed for the onset of AD corrob-
orated the same association between vaccination and reduced AD
risk. In this study, a history of vaccination for tetanus or diphtheria,
and thus likely BP, was associated with a signiﬁcantly reduced risk
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or diagnosis with AD over ﬁve years (RR 0.4, 95% CI: 0.17–0.96)
Tyas et al., 2001).
.3. Case 3: AD in Nigerians and African Americans
During the mid-1990s, a total of 4606 non-demented residents
f Ibadan, Nigeria, and African Americans in Indiana, US, all greater
han 65 years of age, were followed for AD onset with standard-
zed and identical screening, sampling, and diagnostic methods
Hendrie et al., 2001). Bias from cohort attrition, mainly due to
eath, was mitigated by adjustment for mortality. Minor varia-
ion in 4 allele-AD association and differences in vascular disease
etween groups might have accounted for some risk variance. Par-
icipation refusal rates were low in both populations, and few
ifferences were detected between subjects who completed and
ropped out of the study. In sum, detection, attrition, and report-
ng bias were not likely large sources of outcome variation. The
ge-standardized mortality-adjusted annual incidence of AD was
 statistically signiﬁcant 54% lower among Nigerians (1.15%, 95%
I 0.96–1.35%) than African Americans (2.52%, 95% CI 1.40–3.64%)
fter only ﬁve years of observation (Hendrie et al., 2001). In a
revious report from the same investigators, age-adjusted AD
revalence rates were 1.41% in the Nigerian cohort and 6.42% in
he African American cohort (Ogunniyi et al., 2000).
To account for the US-Nigerian AD risk differential, we submit
hat variable rates of subclinical Bordetella pertussis colonization
SCBPC) in the two populations played an important role. In the
HO-deﬁned African region, initial BP vaccination series coverage
as 5% in 1980, 52% in 2000 and 72% in 2012, when US rates were
6%, 94% and 96% respectively (WHO, 2014). We  suggest that low
igerian BP vaccination rates led to high rates of circulating BP,
igh individual BP exposure rates, high rates of latent immuniza-
ion and mucosal BP immunocompetence, and therefore to lower
CBPC and AD rates. In contrast, high US vaccination rates led to low
ates of circulating BP, low individual BP exposure rates, low rates
f latent immunization and mucosal BP immunocompetence, and
o higher SCBPC and AD rates. We  propose that the increased risk for
D in African Americans compared to Nigerians, and more broadly,
he higher risk of AD in more afﬂuent societies (Hendrie et al.,
001; Ukraintseva, 2016; Mathers and Leonardi, 2000), reﬂects a
ifference in BP vaccination and SCBPC rates.
To be clear, the rising age-adjusted risk for AD in the US cor-
elates with, but is not held to be directly caused by, currently
vailable pertussis vaccines which decrease acute clinical BP risk,
ut do not induce protective mucosal immunity, preclude subclin-
cal BP infection (Ward et al., 2005; Zhang et al., 2014; Warfel
t al., 2014) or prevent transmission (Warfel et al., 2014; Long
t al., 1990). Subclinical BP colonization (not pertussis vaccination
r acute clinical BP) is proposed to directly increase AD risk.
. Plausibility of nasopharyngeal Bordetella pertussis
nfection and AD
.1. Subclinical nasopharyngeal Bordetella pertussis
olonization is common
BP infection is not commonly reported in adults, rates of
ubclinical infection are underappreciated, and SCBPC has been
ocumented in multiple populations and age groups. In a highly
99%) vaccinated region in China in 2011, during a period without
 recent BP outbreak, 4.8% of 629 asymptomatic children screened
olymerase chain reaction (PCR) positive for BP by nasopharyngeal
wab (Zhang et al., 2014). In a German study of sudden unex-
ected deaths in infants conducted from 1995 to 1997, 5.3% of
41 infants in the control group were colonized with BP, as doc-logy 222 (2017) 228–240
umented by nasopharyngeal swab PCR (Heininger et al., 2004). In
2015, a cross sectional study reported 7.1% of 70 asymptomatic Ira-
nian healthcare workers were positive for BP by nasopharyngeal
culture (Naeini et al., 2015). In a Dutch study, the annual inci-
dence of BP infection in 3–79 year olds between 1995 and 1996, as
determined by serologic assays, was  6.6%, while the annual inci-
dence of notiﬁed cases was just 0.01% (de Melker et al., 2006),
for a ratio of reported to total BP cases of 1 in 660. In a subse-
quent Dutch study quantifying serologic evidence of BP infection
in 2006–2007, 9.3% of those age 9 years and older had signiﬁcantly
elevated levels of anti-pertussis toxin IgG, suggesting BP infection
in the prior year (De Greeff et al., 2010). An Italian study found that
serologic evidence of recent BP infection increased from 9.3% (95%
CI 7.5–11.1%) in 1997 to 14.1% (95% CI 11.4–16.8%) in 2013 (Palazzo
et al., 2016). In the US acellular BP vaccine trial completed in 1999,
rates of undiagnosed BP infections for individuals age 15–65 years
were estimated at 1–10 million cases per year, depending on case
deﬁnition (Ward et al., 2005), in years when the Centers for Dis-
ease Control and Prevention (CDC) reported approximately 7000
US cases annually (http://www.cdc.gov/pertussis/surv-reporting/
cases-by-year.html). The ratio of reported to undiagnosed BP cases,
comparing data from the Ward study to concurrent CDC data,
ranges from 1 in 140 to 1 in 1400. In summary, over the past two
decades multiple studies from across the globe document SCBPC
rates greatly in excess of reported BP infection rates, including
evidence from highly vaccinated populations.
3.2. Viability of a nose to brain pathway
Given documentation of nasopharyngeal BP colonization in
multiple populations, we  examine the potential for SCBPC-secreted
toxins to access the CNS. While a detailed understanding of the
nose to brain pathway is still emerging, extensive evidence sup-
ports its viability (Ferreyra-Moyano and Barragan, 1989; Malerba
et al., 2011; Illum, 2004; Doty, 2008; Landis et al., 2012), and multi-
ple prior authors have suggested that pathogens access the CNS via
an olfactory route (Merril, 2012; Ferreyra-Moyano and Barragan,
1989; Doty, 2008; Gay, 2007) and may  lead to neurodegenerative
disease (Merril, 2012; Ferreyra-Moyano and Barragan, 1989; Doty,
2008). For purposes of this paper, the “nose” is meant to include the
nasal cavity, nasopharynx and proximate structures with ciliated
mucosal surfaces, including the paranasal sinuses.
BP is primarily transmitted from person to person by expelled
airborne droplets from an infected individual (Broder et al., 2006),
and once inhaled, can bind to mucosal ciliated respiratory epithe-
lium that lines much of the respiratory tract (Dahl and Mygind,
1998). In addition, the nasal turbinates direct a portion of inspired
air to ciliated olfactory epithelium of the superior nasal cavity (Elad
et al., 1993), to which BP readily adheres (Mattoo and Cherry, 2005).
With advanced age, respiratory epithelium can replace olfactory
neuroepithelium at the superior nasal mucosa providing additional
surface area for BP attachment adjacent to olfactory nerves, and this
transition may  occur more rapidly in those with AD (Hawkes, 2003;
Yamagishi et al., 1994). Sensory olfactory nerves are also ciliated
(Jenkins et al., 2009), providing an additional adhesive foothold for
BP. As olfactory nerves pass through channels in the boney crib-
riform plate to terminate in the forebrain at the olfactory bulb
(Jansson, 2004), they provide direct communication from the nasal
cavity to the CNS and a path of travel for BP toxins secreted by an
SCBPC infection in a mucosally BP-immunodeﬁcient host.
Multiple intranasally administered drugs travel rapidly to the
olfactory bulb, and the brief transit interval (5–90 min) suggests
extracellular transport (Chapman et al., 2013). Mammalian studies
demonstrate the passage of neuropeptides from the nose to brain
without entering the bloodstream (Illum, 2000; Born et al., 2002),
and Balin et al. established a direct extracellular pathway from
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ose to brain by observing that, in mammalian models, intranasal
orseradish peroxidase reaches the olfactory bulbs of the CNS
ithin 45–90 min  (Balin et al., 1986).
In addition to migration along the path of olfactory nerves,
t is possible that BP toxin reaches the CNS via absorption from
he nasal mucosa into nasal capillaries and circulation, eventually
raversing the circumventricular organs (CVOs). CVOs are midline
eriventricular brain tissues, including the choroid plexus, median
minence, neurohypophysis, subfornical organ, organ vasculosum
r lateral terminalis, area postrema, and the pineal gland (Johnson
nd Gross, 1993; Schulz and Engelhardt, 2005). These tissues lack
he usual tight endothelial junctions of the blood-brain barrier
BBB), which allow for the physiologic passage of pituitary neuroen-
ocrine hormones (Fry and Ferguson, 2007), while maintaining a
ore permeable boundary between the peripheral circulation and
he CNS. Broadwell and Sofroniew have shown that serum pro-
eins with mass of up to 500 kilodlatons (kDa) may  access the CNS
nd cerebrospinal ﬂuid (CSF) via CVOs (Broadwell and Sofroniew,
993). By comparison, the mass of BP toxin is 105 kDa (Locht et al.,
011), well within size parameters for CVO-mediated passage into
he CNS, though solubility and other factors may  also play a role.
While migration of BP toxin into the CNS may  not require facil-
tation beyond passage via olfactory nerve channels and CVOs, we
ote that BP toxin also impairs BBB integrity (Kügler et al., 2007,
erfoot et al., 2004), which is compromised in AD (Ujiie et al., 2003).
.3. The neuroanatomic link between olfactory dysfunction,
asopharyngeal SCBPC, and AD
Impaired olfactory detection and identiﬁcation are common in
D, and olfactory dysfunction predicts progression from mild cog-
itive impairment to AD, and increases with AD severity (Arnold
t al., 2010; Attems et al., 2005; Devanand et al., 2000; Roberts et al.,
015). Anosmia confers twice the risk of cognitive loss compared
ith those with normal olfactory function over just two years of
ollow up, and ﬁve times the cognitive risk in those with a single
POE4 allele (Graves et al., 1999).
Deﬁcits in odor detection may  be due to olfactory sensory
athology observed at mucosal surfaces in AD (Yamagishi et al.,
994; Touhara, 2002; Bruch and Kalinoski, 1987), and postmortem
uman studies demonstrate increased levels of A and paired
elical ﬁlament-tau in the olfactory epithelium of AD patients com-
ared with controls. In addition, preliminary data demonstrate
igher levels of tau protein, including phosphorylated tau, in nasal
ecretions of anosmic AD patients compared with controls (Passali
t al., 2015), consistent with the presence of peripheral (intranasal)
lfactory pathology in AD. Notably, co-administration of tau pro-
ein and adjuvant including BP toxin produces CNS neuroﬁbrillary
angles, axonal damage, and gliosis consistent with AD (Rosenmann
t al., 2006) (see Section 4.3). Further, since part of odor discrimina-
ion is mediated by BP toxin sensitive G-protein coupled olfactory
eceptors (Touhara, 2002; Bruch and Kalinoski, 1987), e.g. Go/i, com-
onents of odor signal transduction may  be inhibited by secreted
P toxin (Ignatious Raja et al., 2014; Von Dannecker et al., 2005),
ontributing to olfactory deﬁcits in AD.
As illustrated in Fig. 1, the anatomic location of SCBPC in the
uperior aspect of the nasal cavity, just inferior to the cribriform
late, is contiguous with neurologic projections into the CNS, paral-
eling the observed distribution of AD pathology. Affected proximal
tructures in AD include the olfactory epithelium, olfactory tract,
lfactory bulb, primary olfactory cortices and their projections
Attems et al., 2014). Notably, a large autopsy study documented
he correlation between Braak stage in AD and the degree of
lfactory bulb deposition of A, neuritic plaque and -synuclein
p < 0.001) (Attems et al., 2014). Observed deﬁcits in odor identiﬁ-
ation, and potentially detection, may  also be due to more centrallogy 222 (2017) 228–240 231
olfactory neuropathology and cognitive changes in AD (Serby et al.,
1991; Nordin and Murphy, 1996; Hawkes and Shephard, 1998;
Sakuma et al., 1996).
Primates retain direct projections from the olfactory tract to the
hippocampus and amygdala, which not only suggests an important
relationship between the olfactory and limbic systems (Zald and
Pardo, 1997), but also provides an anatomic route for the transport
of BP toxin from an SCBPC within the nasal cavity to these brain
regions. As discussed in detail in Section 4 below, there are multi-
ple mechanisms by which BP toxin may  promote neuropathology
consistent with AD. Ferreyra-Moyano and Barragan argued that
since classic AD pathology in autopsied AD brains preferentially
involves the olfactory and entorhinal cortices, the amygdala and the
hippocampus, and because each of these brain regions receives pri-
mary or secondary projections from the olfactory bulb, the olfactory
system likely plays a role in the pathogenesis of AD (Ferreyra-
Moyano and Barragan, 1989).
Braak et al. classiﬁed AD into neuropathological stages, with
pathologic progression over time and space, wherein cortical dis-
ease is ﬁrst noted in the transentorhinal region of the temporal
lobe (Braak and Braak, 1996; Braak and Del Tredici, 2013; Braak
et al., 2011). Histologic mapping demonstrates that olfactory bulb
pathology occurs early in AD (Braak stage 0 or 1, of 6 stages) (Hyman
et al., 1990; Loopuijt and Sebens, 1990). A study of 40 deﬁnitive AD
cases detailed tau pathology in the olfactory system, while another
series used tau immunohistochemistry to document olfactory AD
pathology (Attems et al., 2005; Kovacs et al., 1999). As Kovacs et al.
summarized, in AD “The most severely affected areas are inter-
connected with the central olfactory system, in contrast with the
relative sparing of other sensory areas without olfactory connec-
tions” (Kovacs et al., 1999).
Dystrophic olfactory neurites (Arnold et al., 2010) and cerebral
atrophy are also common in AD, with hippocampal loss more than 4
times greater in AD than in controls (Leung et al., 2013). Character-
istic progressive cerebral atrophy of AD positively correlates with
Braak stage, with early regional brain changes in AD projecting from
the olfactory tract (e.g. entorhinal cortex, anterior hippocampus),
then spreading to the parietal lobes, temporoparietal association
cortices, and the frontal lobes (Whitwell et al., 2007). Importantly,
in the pre-vaccine era when deaths due to pertussis were high, Lit-
vak et al. observed that cerebral atrophy was the most common
cerebral complication of BP (Litvak et al., 1948), and Ford demon-
strated that post-pertussis CNS neuropathology included cerebral
cortical neurodegeneration, most notably in the hippocampus and
frontal cortex (Ford, 1929), consistent with AD.
Beyond regional cerebral pathology, BP-mediated injury to
even a single cell in the olfactory tract might lead to a “tip-
ping the ﬁrst domino” effect with pathologic consequences to
neurally connected limbic structures, such as the hippocampus
and amygdala. As previously summarized by Hardy and Revesz,
AD may  progress as a result of “spreading of disease—for exam-
ple, between adjacent neurons in a pathway” (Hardy and Revesz,
2012). Liu et al. used mice transfected to express human tau
to demonstrate sequential propagation of tau pathology from
the entorhinal cortex along anatomically connected neural net-
works with apparent trans-synaptic spread (Liu et al., 2012).
BP toxin localized to a single neuron leading to constitutive
cyclic adenosine monophosphate (cAMP) production (via Gi inhi-
bition), protein kinase A (PKA) activation, and the subsequent
upregulated phosphorylation of multiple substrates (e.g. tau, G-
protein-coupled receptor kinase 2) is an example of such a
potential BP-mediated ﬁrst domino scenario (see Sections 4.4 and
4.14).
Others have shown that A production can be increased in
mice transfected to overexpress human amyloid precursor pro-
tein, through the introduction of A “seeds” into the CNS, with
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Fig. 1. Sagittal illustration of the human head demonstrating inhalation of Bordetella pertussis and localization to the superior nasal cavity. Note the close anatomic relationship
between the natural habitat of BP colonization at the ciliated epithelium of the superior nasal cavity, and the adjacent olfactory nerves that pass through channels in the
boney  cribriform plate to enter the CNS at the olfactory bulb. We  propose that BP toxin secreted by SCBPC in the superior nasal cavity can ascend along the olfactory tract
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ippocampus and amygdala.
atterns of A deposition approximating those observed in nor-
al  age-related deposition and AD, e.g. favoring the hippocampus
Eisele et al., 2009). As discussed in detail in Sections 4.1, 4.5 and
.6, BP toxin may  initiate and perpetuate A accumulation to pro-
ote neuropathology characteristic of AD, given BP toxin’s ability
o induce A (McManus et al., 2014) and A-generating BACE1
Hartlage-Rübsamen et al., 2003), and reduce A clearance (Tahara
t al., 2006; Chen et al., 2006). These ﬁndings suggest that small
mounts of A and abnormal tau, triggered by BP toxin, might ini-
iate a cascade of protein deposition contributing to AD pathology,
ith propagation analogous to that seen in prion disease (Jucker
nd Walker, 2011; Guo et al., 2006, Tatarnikova et al., 2015).
In summary, AD pathology may  sequentially progress through
he CNS, starting with peripheral olfactory structures, tracking
long neuroanatomic networks to the transentorhinal cortex and
ntorhinal cortex, the hippocampus and temporal neocortex and
o other brain regions—a scenario consistent with nasally initiated,
CBPC-mediated, neuropathology. Given the proximity of the CNS
o BP-hospitable mucosal surfaces of the superior nasal cavity, the
ontiguity of these ciliated epithelial BP binding sites and olfactory
erves which pass through the cribriform plate into the forebrain,
he unusual ability of BP toxin to compromise the BBB, and the doc-
mented association between acute clinical BP and AD-stereotypic
europathology, it is possible, if not probable, that BP toxin secreted
y SCBPC infections accesses the CNS in some infected individu-
ls. Potential pathology due to BP toxin activity within the CNS is
iscussed below in light of experimentally induced BP-mediated
isease that is highly consistent with the hallmark pathologies of
D.o brain structures projecting from the olfactory bulb such as the entorhinal cortex,
4. Mechanistic evidence supporting BP infection in AD
We  review ﬁfteen mechanisms by which BP infection may  pro-
mote the development of AD. Among the evidence, BP or BP toxin
(1) increases production and decreases clearance of A ﬁbrils,
which comprise neuritic plaques, (2) increases production of hyper-
phosphorylated tau and neuroﬁbrillary tangles, and (3) promotes
CNS inﬂammation and neural excitotoxicity—neuropathology
highly characteristic of AD. In addition, we note the deleterious
interaction between infection and carriage of the APOE4 allele,
provide insight into mechanisms by which BP can induce mito-
chondrial dysfunction and oxidative stress, lead to AD as so-called
“type 3 diabetes”, and disrupt the structure and function of the Golgi
apparatus and endoplasmic reticulum to cause pathologic protein
aggregation as observed in AD.
4.1. Respiratory infection with BP induces hallmark AD pathology
Perhaps the most striking evidence for the potential role of
BP in AD are the important experiments conducted by McManus
et al. demonstrating that respiratory (inhaled) infection with BP in
APP/PS1 mice, transgenic for enhanced CNS human amyloid pre-
cursor protein production, signiﬁcantly increases A-containing
plaques in the hippocampus and frontal cortex (McManus et al.,
2014), recapitulating neuropathology typical of AD. In addition,
these experiments establish that respiratory BP infection induces
other AD-typical ﬁndings including CD4+ T helper 1 (Th1) lympho-
cyte and CD4+ T helper 17 (Th17) lymphocyte brain inﬁltration,
and increased cortical expression of CD11b messenger ribonu-
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leic acid (mRNA) and glial ﬁbrillary acidic protein mRNA—markers
f CNS microglial activation and astroglial activation respectively
Kalla et al., 2003; Webster et al., 2006). These changes increase
ith mouse age and time since BP exposure (progression occurs
ven after infection clears), with McManus et al. suggesting, “infec-
ion may  be a major environmental factor in the progression
f AD-like pathology” (McManus et al., 2014). Considering the
otality of evidence presented herein, we go further to propose
hat more speciﬁcally, Bordetella pertussis is an important human
europathogen and that subclinical BP colonization (SCBPC) is a
reviously unidentiﬁed major cause of AD. We  submit that AD neu-
opathology may  be initiated by nasopharyngeal SCBPC, with local
ecretion of BP toxin. As noted in Section 2.3, SCBPC is more com-
on  among individuals in highly BP vaccinated populations with
ow circulating levels of BP. Such individuals possess poor mucosal
P immunity due to reduced BP exposure and thus reduced latent
P immunization, compounded by the inability of currently avail-
ble BP vaccines to induce potent and effective mucosal immunity
Zhang et al., 2014; Warfel et al., 2014). Poor mucosal BP immunity,
n turn, is held to increase the risk of SCBPC infection, and thus AD.
.2. Respiratory BP infection induces CNS inﬂammatory changes
onsistent with AD
In addition to activating CNS microglia and astroglia (McManus
t al., 2014; Kalla et al., 2003; Webster et al., 2006), respiratory BP
nfection can upregulate the inﬂammatory cytokines interleukin
 (IL-1) and tumor necrosis factor- (TNF-)  in the hippocam-
us (Loscher et al., 2000), a brain region characteristically affected
n AD. Importantly, “...TNF- and IL-1 increase expression of APP
APP] and A, suggesting that CNS inﬂammation may  in fact
mplify amyloid deposition” (Holmes and Cotterell, 2009). Even
t picomolar concentrations, BP toxin inhibition of Gi proteins can
irectly lead to reduced microglial branching, a hallmark of the
icroglial activation and neuroinﬂammation observed in AD (Kalla
t al., 2003; Grifﬁn, 2013).
Experimental models also demonstrate that respiratory BP
nfection upregulates the pro-inﬂammatory cytokine interleukin
 (IL-6) in the hippocampus and hypothalamus (Loscher et al.,
000), consistent with elevated cerebrospinal ﬂuid IL-6 levels in
D patients (Blum-Degena et al., 1995).
.3. Co-administration of tau and BP toxin produces
euroﬁbrillary tangles
Mice injected with recombinant human tau protein and adju-
ant including BP toxin develop CNS neuroﬁbrillary tangles, axonal
amage, and gliosis consistent with AD pathology (Rosenmann
t al., 2006). Just as AD patients produce higher levels of anti-
au antibodies compared to patients with non-AD dementia and
on-demented controls (Bartos et al., 2012), all mice immunized to
au in this study developed anti-tau antibodies (Rosenmann et al.,
006).
Given the presence of tau protein in the olfactory epithelium of
lderly human adults without AD (Arnold et al., 2010; Trojanowski
t al., 1991), and in nasal secretions of anosmic adults without AD
Passali et al., 2015), and given the signiﬁcant prevalence of SCBPC,
t is anticipated that tau, co-localized with BP toxin secreted from
n SCBPC, manifests the neuroﬁbrillary tangles, axonal damage and
liosis produced in experimental models (Rosenmann et al., 2006),
ontributing to neuropathology in AD.
.4. BP toxin-mediated cAMP-dependent PKA dysregulation is
onsistent with tau hyperphosphorylation
BP toxin induces constitutive production of cAMP (Katada, 1982)
hich activates PKA (Seino and Shibasaki, 2005), which in turnlogy 222 (2017) 228–240 233
phosphorylates tau (Scott et al., 1993). Thus, BP toxin-mediated
constitutive production of cAMP can lead to hyperphosphoryla-
tion of PKA substrates, including tau. Tau hyperphosphorylation by
PKA induces the paired helical ﬁlaments of NFTs (Zheng-Fischhöfer
et al., 1998). Hyperphosphorylated tau is a hallmark of AD and is
thought to lead to the formation of insoluble tau, microtubule insta-
bility and abnormal aggregation of tau isoforms (Anderson et al.,
2009; Schneider et al., 2004; Buee et al., 2000) commonly observed
in AD (Zheng-Fischhöfer et al., 1998). As one group noted, “. . .the
clinical progression of Alzheimer’s disease correlates with distribu-
tion and amount of tau aggregates. . .[and] A common hypothesis
holds that tau hyperphosphorylation and subsequent detachment
increases the pool of unbound tau beyond a critical concentration,
thereby initiating its aggregation into paired helical ﬁlaments (gain
of toxic function)” (Schneider et al., 2004).
In addition, tau dephosphorylation by endogenous phos-
phatases may  be inhibited by BP toxin, given that BP toxin inhibits
certain protein phosphatases (Buee et al., 2000; Chen et al., 1998).
4.5. BP induces ˇ-site AˇPP-cleaving enzyme, BACE1
BACE1 is produced by neurons and astrocytes and is required
for the generation of A (Tanzi and Bertram, 2005). BP induces
astrocyte BACE1 expression in a murine model using systemi-
cally administered adjuvant including BP to activate glial cells
in mice transgenic for the human AD-associated APP mutant
(K670N-M671L) gene from a family with early-onset AD (Hartlage-
Rübsamen et al., 2003). In this study, astrocytes induced to produce
BACE1 were noted “in close proximity” to CNS A plaques, sug-
gesting that BP toxin localized to astrocytes may induce BACE1 and
thereby lead to A plaque formation.
4.6. BP toxin reduces A  ˇ clearance
BP toxin dramatically reduces microglial clearance of ﬁbrillar
A in vivo in a murine AD model mutant for toll-like receptor 4, a
receptor linked to microglial activation and A clearance (Tahara
et al., 2006). In addition, toll-like receptor 2-activated microglial
internalization of A is inhibited by BP toxin (Chen et al., 2006).
4.7. The APOE4 allele may alter inﬂammatory responses to
infection and favor the development of AD
APOE allelic variation may  contribute to AD pathology through
numerous mechanisms (Bu, 2009). Prior investigators have pro-
posed that neurotropic infection is a risk factor for AD in those who
carry the APOE4 allele (Itzhaki et al., 2004) and “. . .the risk of
developing AD is increased by infection or general ill health, and a
particular susceptibility to infection may  be conferred by the ApoE
e4 allele” (McManus et al., 2014). Animal data also suggest that
presence of the APOE4 allele confers increased permeability of
the blood-brain barrier (Nishitsuji et al., 2011), which may  increase
CNS susceptibility to penetration by BP toxin.
Animal data support immunologic and inﬂammatory responses
to bacterial toxins which promote AD neuropathology in carriers of
the APOE4 allele (Zhang et al., 2010). For example, in experimen-
tal autoimmune encephalomyelitis using BP toxin as an adjuvant,
APOE4-transgenic mice demonstrate AD-stereotypic tasks, such
as deﬁcits in spatial learning and recall (Tu et al., 2009). In this
model, choline acetyltransferase is reduced in the hippocampus (Tu
et al., 2009), just as decreases in hippocampal choline acetyltrans-
ferase activity correlate with cognitive loss in AD (Pappas et al.,
2000).
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.8. BP toxin increases excitotoxic neural glutamate release
Glutamate is the major excitatory CNS neurotransmitter in
ammals where it mediates fast synaptic transmission, and excito-
oxic cell death results from prolonged depolarization of neurons,
s seen in AD (Doble, 1999; Hynd et al., 2004). Glutamate release
rom CNS neurons includes cAMP and PKA dependent mecha-
isms (Herrero and Sánchez-Prieto, 1996), levels of which can
e increased through Gi/0 inhibition of glutamate receptors sen-
itive to BP toxin (Katada, 1982; Padgett and Slesinger, 2010). BP
oxin increases neuronal glutamate release (Cullen et al., 1994;
uston et al., 1993) and converts adenosine induced inhibition
f neural glutamate release to stimulation of neural glutamate
elease (Dolphin and Prestwich, 1985). Compounding this excito-
oxic increase in glutamate release is the ability of BP toxin to inhibit
i/o gamma-aminobutyric acid B (GABAB) receptors, which mediate
ertain neuroinhibitory functions in the CNS (Padgett and Slesinger,
010). In sum, it is plausible that BP toxin increases CNS glutamate-
ediated excitotoxicity while decreasing GABAB neuroinhibition,
romoting excitotoxicity as seen in AD, essentially “depressing the
ccelerator while releasing the break.”
.9. BP toxin inhibits secretion of brain-derived neurotrophic
actor (BDNF)
BDNF supports the maintenance and repair of neurons and is
xpressed in multiple brain regions, including the hippocampus
Binder and Scharfman, 2004) and olfactory bulb (Mast and Fadool,
012), areas preferentially affected in AD (Attems et al., 2014; Braak
t al., 2011). BDNF is neuroprotective against A in vivo (Arancibia
t al., 2008). Function-blocking anti-BDNF antibodies impair both
hort-term and long-term memory formation in mice (Alonso et al.,
002), such that impaired BDNF activity replicates memory deﬁcits
een in AD. Notably, BDNF levels are depressed in AD (Henry et al.,
010).
Consistent with these observations, BP toxin inhibits the secre-
ion of BDNF (Gunther et al., 2000) from CNS neurons in vivo, and
ay  also inhibit calcitonin gene-related peptide (CGRP) enhanced
DNF release, as the CGRP receptor is BP toxin sensitive (Buldyrev
t al., 2006). If BP toxin were to access the hippocampus or other
reas of the brain that rely on BDNF for neurotrophic support, it
s plausible that BP toxin-induced decreased BDNF activity would
ontribute to neuropathology in AD.
.10. BP toxin inhibits Wnt  signaling
For more than 15 years, Wnt  signaling has been proposed
o inﬂuence multiple pathologic mechanisms in AD: “. . .loss of
unction of Wnt  signaling components would trigger a series of
isrecognition events, determining the onset and development of
D” (De Ferrari and Inestrosa, 2000). For example, Wnt  signal-
ng regulates adult hippocampal neurogenesis (Lie et al., 2005),
—induced neuroinﬂammation and neurotoxicity (Li et al., 2011),
nd -catenin dependent and independent proinﬂammatory acti-
ation of microglia (Halleskog and Schulte, 2013). Since BP toxin
locks several forms of Wnt  signaling (Halleskog and Schulte, 2013;
on and Wong, 2007; Kilander et al., 2011), CNS localized BP toxin
rom an SCBPC may  contribute to AD via compromise of Wnt  path-
ays.
.11. BP toxin inhibits neuronal processes underlying memory
ormationBP toxin inhibits long-term potentiation in hippocampal neu-
ons (Goh and Pennefather, 1989), a mechanism underlying
earning and memory formation (Whitlock et al., 2006). In addi-logy 222 (2017) 228–240
tion, BP toxin reduces synaptic transmission and blocks long-term
depression in corticostriatal synapses, a proposed mechanism in
motor learning and memory (Tang and Lovinger, 2000). By these
and other mechanisms discussed herein, BP toxin can impair mem-
ory, the signature pathology of AD.
4.12. BP toxin blocks neuroprotection by soluble amyloid
precursor protein  ˛ (sAPP˛)
Membrane bound sAPP is neuroprotective in vivo in murine
hippocampal cells, acting via the Akt survival pathway and likely
through inhibition of glycogen synthase kinase 3 (GSK3)-
induced apoptosis (Milosch et al., 2014). Akt activation is mediated
by signal transducing G proteins sensitive to BP toxin, adminis-
tration of which abolishes sAPP-mediated cell survival (Milosch
et al., 2014). In sum, BP toxin inhibits a neural rescue pathway,
which may exacerbate apoptotic cell loss in AD.
4.13. BP induces mitochondrial dysfunction and oxidative stress
Mitochondrial dysfunction and oxidative stress have been
implicated in the early pathophysiology of AD, including neu-
ronal pathology induced by reactive oxygen species (Hirai et al.,
2001; Blass and Gibson, 1990; Su et al., 2008). Consistent with
these ﬁndings, BP alters cellular cAMP levels, mitochondrial mem-
brane potentials and adenosine triphosphate (ATP) levels, and can
thereby lead to BP induced apoptosis (Bachelet et al., 2002). In
addition, BP toxin possesses nicotinamide adenine dinucleotide
(NAD+) glycohydrolase activity (Locht et al., 2011; Kaslow and
Burns, 1992) which can deplete cytosolic NAD+ (a coenzyme in
redox reactions) and thereby lead to glycolytic failure, mitochon-
drial membrane depolarization and altered permeability which can
stimulate apoptosis-inducing factor release, and neuronal death
(Alano et al., 2010). Since NAD+ levels decrease in degenerat-
ing neurons and preserved axonal NAD+ levels protect against
neurodegeneration (Wang et al., 2005), BP-mediated depletion of
cellular NAD+ may  contribute to AD neurodegeneration. BP also
induces leukocyte production of hydrogen peroxide (Steed et al.,
1992), which decomposes to form hydroxyl radicals that can lead
to oxidative damage (Barber et al., 2006). Further, in the experimen-
tal autoimmune encephalomyelitis model, BP toxin contributes
to the induction of subclinical neuronal dysfunction which cor-
relates with oxidative stress, as indicated by over-activation of
nicotinamide adenine dinucleotide phosphate (NADPH) oxidases
(Radbruch et al., 2016).
4.14. BP toxin inhibits CNS insulin receptor activation, abolishes
glucose transporter 4 (GLUT4) translocation, and increases serum
insulin levels
Glucose uptake and utilization is critical to brain function and
is mediated by glucose transporter (GLUT) proteins, which are reg-
ulated by insulin and highly expressed in medial temporal brain
structures, notable sites of AD pathology (de la Monte, 2014).
GLUT4 is expressed in the olfactory bulb, hippocampus, and cor-
tex (Benomar et al., 2006) and brain insulin resistance occurs both
early and frequently in AD (Persiyantseva et al., 2013). The impor-
tance of CNS insulin resistance in neurodegeneration and impaired
brain glucose utilization has led some to refer to AD as “Type 3
Diabetes” (Steen et al., 2005).
In CNS neurons, BP toxin inhibits insulin-stimulated receptor
autophosphorylation, a critical step in insulin receptor activation
(Persiyantseva et al., 2013). In addition, since Gi2 regulates translo-
cation of GLUT4 from the cytosol to the plasma membrane, and
since BP toxin catalyzes ADP-ribosylation and inactivates Gi2, BP
toxin abolishes GLUT4 translocation and thereby impairs glucose
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ransport (Song et al., 2001). Disruption of GLUT4 translocation in
he hippocampus is associated with memory impairment (Winocur
t al., 2005).
Further disruption of CNS glucose uptake may  occur from
P toxin-mediated constitutive activation of cAMP production
Katada, 1982) which, as previously noted (see Section 4.4), reg-
lates PKA signaling (Seino and Shibasaki, 2005). PKA increases
hosphorylation of G-protein-coupled receptor kinase 2 (GRK2)
nd enhances recruitment of GRK2 to the plasma membrane (Li
t al., 2006). GRK2 upregulation is observed in AD (Leosco et al.,
007) and increased GRK2 inhibits both insulin-stimulated GLUT4
ranslocation and uptake of 2-deoxyglucose (Usui et al., 2004), pro-
iding an additional potential BP-mediated mechanism to account
or the insulin resistance (Craft, 2007) and compromised cerebral
lucose metabolism and uptake observed in AD patients (Liu et al.,
008). It is noteworthy that in AD brains, reductions in glucose
ransporter proteins correlate with abnormal hyperphosphoryla-
ion of tau (Liu et al., 2008), another PKA substrate (see Section
.4).
Finally, hyperinsulinemia is associated with higher AD risk and
ecline in memory-related cognitive function (Luchsinger et al.,
004). In rats, hyperinsulinemia leads to “defects in hippocampal
ynaptic plasticity associated with deterioration in spatial learning
nd memory functions” (Kamal et al., 2013). In a human random-
zed crossover trial, moderate hyperinsulemia induction in healthy
dults led to increased CNS cytokine levels, including IL-1, IL-6,
nd TNF-, “. . .agents that interact synergistically to promote A
ynthesis (IL-6 and IL-1) and reduce its clearance (TNF-).” (Fishel
t al., 2005)
Consistent with these observations, BP toxin administered to
nimals and healthy human subjects, even as a single dose, leads
o increased serum insulin levels with “a long duration of action”
Toyota et al., 1980; Yajima et al., 1983). Further, it has been demon-
trated that humans infected with BP can present with increased
erum insulin levels without hypoglycemia (Furman et al., 1988).
f historical interest, BP toxin was formerly known as Islet Activat-
ng Protein for its ability to stimulate pancreatic insulin release and
aise serum insulin levels.
.15. BP toxin disrupts the structure and function of the Golgi
pparatus and endoplasmic reticulum which can lead to protein
ggregation
Characteristic AD histopathology includes CNS protein accu-
ulation with aggregation of both tau and A, and it has been
uggested that “AD results from protein aggregation. . . [which]
epresents a key starter and/or promoter of the disease” (Thal and
ändrich, 2015).
The Golgi Apparatus (GA) is the central cellular organelle in the
ecretory pathway, processing and targeting proteins for distribu-
ion throughout the cell (Nassif et al., 2010). The contribution of GA
ragmentation and dysfunction to the pathogenesis of neurodegen-
rative disease including AD has been previously reviewed (Nassif
t al., 2010; Fan et al., 2008; Gonatas et al., 2006; Nakagomi et al.,
008).
GA size is a reliable index of neuronal activity and postmortem
xamination of AD brains demonstrates GA atrophy and fragmen-
ation with neuronal atrophy in neurons without NFTs (Stieber
t al., 1996). In neurons from the hippocampus, cerebellum, and
coustic and visual cortices of AD brains, there are fewer vacuoles
nd vesicles associated with the GA (Baloyannis, 2015). As previ-
usly summarized, “The morphological alterations of GA, which are
bserved even at the initial stages of AD, . . .favor. . .the hypothesis
hat impairment of trafﬁcking in Golgi cisternae and endosomes
nd ER stress may  be one of the crucial factors in amyloidogen-
sis” (Baloyannis, 2015). Others have “hypothesize[d] that Golgilogy 222 (2017) 228–240 235
fragmentation in AD accelerates APP [APP] trafﬁcking and A
production” (Joshi and Wang, 2015).
Consistent with the disruption of GA structure and function
observed in AD, BP toxin localizes to the GA (Plaut and Carbonetti,
2008), ADP-ribosylates Gi-2 proteins associated with GA (Kugler
et al., 2007), and disrupts the structural integrity of the GA (Kugler
et al., 2007; Hidalgo et al., 1995). Hidalgo et al. determined that
treating cells with BP toxin stimulates GA disassembly and redis-
tribution (Hidalgo et al., 1995). Kugler et al. observed that “In [brain
microvascular endothelial] cells incubated with PT [BP toxin] for
up to 6 h [hours], a progressive dissociation of Golgi structures was
apparent” (Kugler et al., 2007). In short, BP toxin localizes to the
GA and can lead to GA fragmentation that may  thereby initiate and
accelerate AD-typical pathology, including aberrant APP trafﬁck-
ing and production of A.
The endoplasmic reticulum (ER) plays an important role in
post-translational modiﬁcation and maintenance of intracellular
calcium homeostasis, and ER dysfunction and ER stress have been
reported in animal models of AD and postmortem human AD brains
(Li et al., 2015). Intraneuronal A accumulation associated with ER
stress is thought to be an early event in AD, and evidence suggests “a
close linkage between ER-stress and tau pathology” (Li et al., 2015).
Consistent with the disruption of ER structure and function
observed in AD, BP toxin localizes to the ER (Plaut and Carbonetti,
2008) and causes the “redistribution and fragmentation of the ER”,
with loss of “regular parallel arrangement of sheets of rough ER”
and reduced density of smooth ER compared to normal controls
(Wang et al., 2000). Further, the G protein, Gi, also regulates GA-
ER retrograde transport such that the inhibition of Gi proteins by
BP toxin stimulates GA redistribution into the ER (Hidalgo et al.,
1995). Given the potential role of GA-ER retrograde transport in
the processing and “quality control” of misfolded proteins (Hidalgo
et al., 1995; Hammond and Helenius, 1994), dysregulation of this
pathway by BP toxin may  contribute to the characteristic patho-
logic accumulation of misfolded proteins seen in AD (DeToma et al.,
2012).
As a site for calcium storage, the ER also plays a role in calcium
homeostasis (Rao et al., 2002) and abnormal calcium homeostasis
can lead to ER stress (Nassif et al., 2010). BP toxin affects activation
of store-operated calcium channels as represented by inhibition
of vasopressin-stimulated calcium inﬂow (Wang et al., 2000). BP
toxin inhibits thapsigargin-induced calcium inﬂow without impair-
ing calcium release from intracellular stores (Fernando and Barritt,
1994) and also inhibits calcium current depression by somatostatin
and muscarinic agonists (Beech et al., 1992). By these and other
mechanisms, BP toxin can alter cellular calcium homeostasis, dys-
regulating the ER and thus potentially furthering neuropathology
in AD.
Taken together, ER and Golgi dysfunction may  not be the result
of toxic protein aggregates such as A peptides as previously
proposed (Ferreiro et al., 2006; Hitomi et al., 2004). Instead, BP-
mediated disruption of the structure and function of GA and ER may
be primary initiating neuropathogenic events leading to intracel-
lular accumulation of misfolded and toxic protein aggregates, the
aberrant release of extracellular proteins, and neurodegeneration.
Notably, in the presenilin (PS) gene mutations that predispose
to familial AD, ER damage and loss of ER function are observed,
and PS1 mutations further disrupt intracellular calcium homeosta-
sis and sensitize neurons to cell death by promoting ER-mediated
apoptotic proteolysis (Li et al., 2015; Zatti et al., 2006). Combined
with the ability of BP to upregulate BACE1 in the familial early-
onset human AD-associated APP mutant model (see Section 4.5),
these observations provide potential mechanistic links between the
BP-mediated sporadic AD pathology proposed in this paper and
inherited pathogenic mechanisms contributing to familial AD.
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. Assessing causation with the Bradford Hill guidelines
While contributions from both genetic predisposition and envi-
onmental exposures are evident in AD, we summarize evidence for
 novel hypothesis and acquired cause of AD: subclinical Bordetella
ertussis colonization (SCBPC). Better known to induce whooping
ough, BP is largely unappreciated as a frequent colonizer of the
uman nasopharynx. Using case studies and experimental data,
e employ the Bradford Hill criteria as a benchmark of causal val-
dation to assess the relationship between BP and AD, including
trength, consistency, temporality, biological gradient, plausibil-
ty, coherence, and analogy to causally accepted mechanisms (Hill,
965). Hill’s construct organizes our analysis of the evidence for BP
n the etiology of AD.
The BP-AD association is strong, with a statistically signiﬁcant
elative risk of 0.4 (a 60% risk reduction) for the development of
D over 5 years in those over age 65 reporting prior vaccination for
etanus or diphtheria, and thus likely BP. The association between
D and SCBPC is consistent across populations and time, as seen in
he US over the past two decades, and in both Canada and Nigeria
n the 1990s. The association is temporally logical as vaccination
hat commonly includes BP antigens is correlated with a decreased
ubsequent risk of AD, and strikingly, respiratory infection with BP
n animal models precedes the deposition of A plaques in the hip-
ocampus and frontal cortex, and leads to other neuropathology
ighly characteristic of AD. The association exhibits a biologic gra-
ient, as seen with the rising age-adjusted risk for AD in the US since
he early 1990s, coincident with the rise in BP, the only vaccine-
reventable disease in the US increasing in incidence during this
eriod. Causation of AD by BP is plausible and coherent given the
ross-cultural documentation of nasopharyngeal SCBPC, its prox-
mity to the CNS, multiple access routes from the nasal mucosa to
he CNS, the preferential and sequential distribution of AD pathol-
gy in the olfactory pathway and its projections, and the many and
iverse sources of mechanistic corroboration cited. This extensive
xperimental support for BP as a cause of AD includes the ability
f respiratory BP infection to induce A-containing plaques and
ncrease CNS inﬂammation, for BP toxin to reduce clearance of A,
nduce BACE1, produce neuroﬁbrillary tangles in mice when co-
dministered with tau, and preferentially affect APOE4 carriers to
lter inﬂammatory responses to infection that favor the develop-
ent of AD pathology. Further, the hypothesis that BP is a cause of
D parallels our understanding of other diseases that were not ini-
ially recognized as infectious in origin. For example, the role of H.
ylori in peptic ulcer disease (Marshall and Warren, 1984) is anal-
gous to BP in AD in that H. pylori also colonizes the mucous layer
in this case, of the stomach) (Shimizu et al., 1996), may  adhere to
pithelium (Logan, 1996), and causes disease through the release
f enzymes (Mobley, 1996) and toxins (Suerbaum and Michetti,
002), or by eliciting an immune response (Mobley, 1996; Ernst
t al., 1994).
Finally, given that BP has previously been proposed by the
uthors to play a causal role in the etiology of multiple sclerosis
MS) (Rubin and Glazer, 2016), ﬁndings of overlapping pathology
re anticipated and have been previously reported. These ﬁndings
nclude increased hyperphosphorylated tau (Anderson et al., 2009;
artosik-Psujek and Stelmasiak, 2006) and increased A (Odinak
t al., 2008) in the CNS of clinical MS  cases compared to controls,
yperphosphorylation and aggregation of insoluble tau in the prin-
iple animal model of MS  (Schneider et al., 2004; Anderson et al.,
008), “profound” microglial activation in the CNS of both AD and
S patients with “strikingly similar” activation patterns (Dal Biancot al., 2008), and in 8 of 45 MS  brains examined at autopsy “plaque
nd tangle density exceeded the number required for neuropatho-
ogical diagnosis of probable AD” with hippocampal, temporal,
nd entorhinal cortical AD pathology trending greater than thatlogy 222 (2017) 228–240
in age-matched controls age 65 years and older (Dal Bianco et al.,
2008). Also supporting the overlap of MS  and AD pathology are
the presence of high levels of APP in actively demyelinating MS
plaques (Gehrmann et al., 1995), that CD45+ lymphocytes and pro-
inﬂammatory cytokines in the CSF of patients with mild cognitive
impairment (a preclinical stage of AD) were “at levels similar” to
MS patients (Monson et al., 2014), evidence of CNS demyelination in
early and late onset AD (Fornari et al., 2012; Mitew et al., 2010), and
the observation of “similar autobiographical memory impairment”
in MS  and AD (Müller et al., 2013).
6. Conclusion
A Bordetella pertussis based hypothesis for Alzheimer’s disease
accounts for several intriguing epidemiologic observations and
explains all hallmark AD neuropathology. BP is naturally predis-
posed to cause AD in its ability to colonize the human nasopharynx,
co-localize with olfactory nerves which access the CNS, and partic-
ularly for the potent and diverse biologic effects of its eponymous
exotoxin, demonstrated by numerous investigators to induce CNS
pathology consistent with AD. Speciﬁcally, respiratory BP infec-
tion and BP toxin secreted from subclinical BP colonization can
account for the initiation and accumulation of A plaques and
tau tangles, microglial activation and inﬂammation, atrophy and
neurodegeneration, excitotoxicity, distinctive anatomic distribu-
tion and sequential spread of disease, oxidative stress, impaired
glucose utilization, and other characteristic CNS pathology.
Given the conﬂuence of AD and BP-mediated pathology, the high
cross-cultural prevalence of SCBPC, and the lack of preventable or
treatable causes with high attributable risk, research into BP as
an important and preventable cause of AD is warranted. Proba-
tive investigation includes screening for olfactory tract BP-PCR in
mild cognitive impairment (MCI) with its attendant increased risk
of progression to AD, SCBPC surveillance of cohorts followed for MCI
and AD onset, and BP colonization eradication studies with MCI  and
AD as outcome measures. In light of the evidence presented, further
inquiry into the role of subclinical Bordetella pertussis colonization
in the etiology of Alzheimer’s disease offers hope, and presents a
promising new direction for the prevention and treatment of this
emerging, potentially infection-driven, epidemic.
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